Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Statistics
Share Statistics
Jazz Pharmaceuticals has 61.63M shares outstanding. The number of shares has increased by -3.69% in one year.
| Shares Outstanding | 61.63M |
| Shares Change (YoY) | -3.69% |
| Shares Change (QoQ) | 0.46% |
| Owned by Institutions (%) | 96.17% |
| Shares Floating | 58.83M |
| Failed to Deliver (FTD) Shares | 21.93K |
| FTD / Avg. Volume | 1.87% |
Short Selling Information
The latest short interest is 4.53M, so 7.46% of the outstanding shares have been sold short.
| Short Interest | 4.53M |
| Short % of Shares Out | 7.46% |
| Short % of Float | 9.94% |
| Short Ratio (days to cover) | 2.84 |
Valuation Ratios
The PE ratio is 13.6 and the forward PE ratio is 5.07. Jazz Pharmaceuticals's PEG ratio is 0.45.
| PE Ratio | 13.6 |
| Forward PE | 5.07 |
| PS Ratio | 1.87 |
| Forward PS | 1.4 |
| PB Ratio | 1.86 |
| P/FCF Ratio | 5.65 |
| PEG Ratio | 0.45 |
Enterprise Valuation
Jazz Pharmaceuticals has an Enterprise Value (EV) of 5.27B.
| EV / Sales | 1.3 |
| EV / EBITDA | 7.36 |
| EV / EBIT | 3.78 |
| EV / FCF | 3.91 |
Financial Position
The company has a current ratio of 4.46, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.46 |
| Quick Ratio | 3.99 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.1 |
| Debt / FCF | 0.05 |
| Interest Coverage | 3.01 |
Financial Efficiency
Return on Equity is 13.68% and Return on Invested Capital is 7.74%.
| Return on Equity | 13.68% |
| Return on Assets | 4.66% |
| Return on Invested Capital | 7.74% |
| Revenue Per Employee | $1.45M |
| Profits Per Employee | $200.04K |
| Employee Count | 2,800 |
| Asset Turnover | 0.34 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -89.77M |
| Effective Tax Rate | -19.09% |
Stock Price Statistics
The stock price has increased by 6.14% in the last 52 weeks. The beta is 0.42, so Jazz Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 0.42 |
| 52-Week Price Change | 6.14% |
| 50-Day Moving Average | 125.25 |
| 200-Day Moving Average | 118.7 |
| Relative Strength Index (RSI) | 54.06 |
| Average Volume (20 Days) | 1.18M |
Income Statement
In the last 12 months, Jazz Pharmaceuticals had revenue of 4.07B and earned 560.12M in profits. Earnings per share was 9.06.
| Revenue | 4.07B |
| Gross Profit | 4.07B |
| Operating Income | 716.63M |
| Net Income | 560.12M |
| EBITDA | 716.63M |
| EBIT | 708.45M |
| Earnings Per Share (EPS) | 9.06 |
Balance Sheet
The company has 2.41B in cash and 69.94M in debt, giving a net cash position of 2.34B.
| Cash & Cash Equivalents | 2.41B |
| Total Debt | 69.94M |
| Net Cash | 2.34B |
| Retained Earnings | 1.13B |
| Total Assets | 12.01B |
| Working Capital | 3.59B |
Cash Flow
In the last 12 months, operating cash flow was 1.4B and capital expenditures -48.07M, giving a free cash flow of 1.35B.
| Operating Cash Flow | 1.4B |
| Capital Expenditures | -48.07M |
| Free Cash Flow | 1.35B |
| FCF Per Share | 21.8 |
Margins
Gross margin is 100%, with operating and profit margins of 17.61% and 13.77%.
| Gross Margin | 100% |
| Operating Margin | 17.61% |
| Pretax Margin | 11.56% |
| Profit Margin | 13.77% |
| EBITDA Margin | 17.61% |
| EBIT Margin | 17.61% |
| FCF Margin | 33.12% |
Dividends & Yields
JAZZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 7.36% |
| FCF Yield | 17.7% |
Analyst Forecast
The average price target for JAZZ is $179, which is 52.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $179 |
| Price Target Difference | 52.9% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 1.55 |
| Piotroski F-Score | 9 |